Comis R L
Department of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19111.
Semin Oncol. 1992 Dec;19(6 Suppl 13):45-50.
Developments in the treatment of extensive small cell lung cancer have proven effective in palliative management but have not yielded improvements in the cure rate for this disease. Strategies involving dose escalation of chemotherapy, including de novo and late intensification dose escalation and dose escalation with growth factor support, have had mixed results in this patient population. Alternating chemotherapy, especially with regimens containing etoposide, has achieved better results overall but has not had a significant impact on survival. Current treatment goals should therefore be focused on short-term palliation of symptoms, at least until more effective drugs are developed. Exploration of resistance modulation strategies and biologic approaches, as well as determining the true value of protracted etoposide treatment, may play a role in future treatment endeavors.
广泛期小细胞肺癌的治疗进展已证明在姑息治疗中有效，但尚未提高该疾病的治愈率。涉及化疗剂量递增的策略，包括从头开始和晚期强化剂量递增以及生长因子支持下的剂量递增，在该患者群体中取得了喜忧参半的结果。交替化疗，尤其是使用含依托泊苷的方案，总体上取得了更好的效果，但对生存率没有显著影响。因此，当前的治疗目标应集中在症状的短期缓解上，至少在开发出更有效的药物之前如此。探索耐药性调节策略和生物学方法，以及确定长期使用依托泊苷治疗的真正价值，可能在未来的治疗努力中发挥作用。
